Everything below concerns acetylated peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-02. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
=== Purge gas === Purge gas is used to control the sample environment, in order to reduce signal noise and to prevent contamination. Mostly nitrogen is used and for temperatures above 600 °C, argon can be utilized to minimize heat loss due to the low thermal conductivity of argon. Air or pure oxygen can be used for oxidative tests like oxidative induction time and He is used for very low temperatures due to the low boiling temperature (~4.2K at 101.325 kPa ).
Christian P. R. Hackenberger (b. Osnabruck, 1976) is a German chemist. He is a professor of Chemical Biology at the Humboldt University of Berlin and heads the research unit Biomolecule Modification and Delivery at the Leibniz Research Institute for Molecular Pharmacology. He is a co-founder of the Munich-based biotech company Tubulis.
Posterior pituitary In the hypothalamic–pituitary–adrenal axis, neurohypophysial hormones are released from the posterior pituitary, which is actually a prolongation of the hypothalamus, into the circulation.
CPGS – Council of Protestants in Guiding and Scouting DESMOS – International Link of Orthodox Christian Scouts ICCS – International Catholic Conference of Scouting IFJS – International Forum of Jewish Scouts IUMS – International Union of Muslim Scouts WBSB – World Buddhist Scout Brotherhood Won-Buddhist Scout Council The Church of the Latter Day Saints
Sources: en.wikipedia.org
=== 1970s to 2011 === Though e-commerce on the dark web started around 2006, illicit goods were among the first items to be transacted using the internet, when in the early 1970s students at Stanford University and Massachusetts Institute of Technology used the ARPANET to coordinate the purchase of cannabis. By the end of the 1980s, newsgroups like alt.drugs would become online centres of drug discussion and information; however, any related deals were arranged entirely off-site directly between individuals. With the development and popularization of the World Wide Web and e-commerce in the 1990s, the tools to discuss or conduct illicit transactions became more widely available. One of the better-known web-based drug forums, The Hive, launched in 1997, serving as an information sharing forum for practical drug synthesis and legal discussion. The Hive was featured in a Dateline NBC special called The "X" Files in 2001, bringing the subject into public discourse. From 2003, the "Research Chemical Mailing List" (RCML) would discuss sourcing "Research Chemicals" from legal and grey sources as an alternative to forums such as alt.drugs.psychedelics. However Operation Web Tryp led to a series of website shut downs and arrests in this area. Since the year 2000, some of the emerging cyber-arms industry operates online, including the Eastern European "Cyber-arms Bazaar", trafficking in the most powerful crimeware and hacking tools. In the 2000s, early cybercrime and carding forums such as ShadowCrew experimented with drug wholesaling on a limited scale.
=== Immunology === Immunoproteomics is and has been used to increase scientific understanding of both autoimmune disease pathology and progression. Using biochemical techniques, gene and ultimately protein expression can be measured with high fidelity. With this information, the biochemical pathways causing pathology in conditions such as multiple sclerosis and Crohn's disease can potentially be elucidated. Serum antibody identification in particular has proven to be very useful as a diagnostic tool for a number of diseases in modern medicine, in large part due to the relatively high stability of serum antibodies. Immunoproteomic techniques are additionally used for the isolation of antibodies. By identifying and proceeding to sequence antibodies, scientists are able to identify potential protein targets of said antibodies. In doing so, it is possible to determine the antigen(s) responsible for a particular immune response. Identification and engineering of antibodies involved in autoimmune disease pathology may offer novel techniques in disease therapy.
Eventually the funk project broke up, and in 1987 Staley joined Cantrell's band on a full-time basis. Two weeks after the band's formation, they were playing a gig at Washington State University, trying to fill in a 40-minute set with a couple of original songs along with Hanoi Rocks and David Bowie covers. The band played a couple of gigs in clubs around the Pacific Northwest, calling themselves different monikers, including Diamond Lie, the name of Cantrell's previous band, and "Fuck", before eventually adopting the name that Staley's previous band had initially flirted with, Alice in Chains. Staley contacted his former bandmates and asked for permission to use the name. Nick Pollock was not particularly thrilled about it at the time, and thought he should come up with a different name; both he and James Bergstrom ultimately gave Staley their blessing to use the name.
The yeast genus Saccharomyces (sugar mold) is favored for winemaking (for both grapes as well as other fruit wines in addition to being used in brewing and breadmaking) because of the generally reliable and positive attributes it can bring to the wine. These yeasts will usually readily ferment glucose, sucrose and raffinose and metabolize glucose, sucrose, raffinose, maltose and ethanol. However, Saccharomyces cannot ferment or utilize pentoses (such as arabinose) which is usually present in small amount in wines as residual sugars. In addition to Saccharomyces cerevisiae, other species within the genus Saccharomyces that are involved with winemaking include:
== Research == Medical authorities generally recommend obtaining beta-carotene from food rather than dietary supplements. A 2013 meta-analysis of randomized controlled trials concluded that high-dosage (≥9.6 mg/day) beta-carotene supplementation is associated with a 6% increase in the risk of all-cause mortality, while low-dosage (<9.6 mg/day) supplementation does not have a significant effect on mortality. Research is insufficient to determine whether a minimum level of beta-carotene consumption is necessary for human health and to identify what problems might arise from insufficient beta-carotene intake. However, a 2018 meta-analysis mostly of prospective cohort studies found that both dietary and circulating beta-carotene are associated with a lower risk of all-cause mortality. The highest circulating beta-carotene category, compared to the lowest, correlated with a 37% reduction in the risk of all-cause mortality, while the highest dietary beta-carotene intake category, compared to the lowest, was linked to an 18% decrease in the risk of all-cause mortality.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.